“The pace of innovation, the profound potential to help patients, the revolutionary impact on health care… all of this makes the field of genome editing truly exceptional,” ASGCT member and Editas Medicine CEO Katarine Bosley said in her testimony.
Washington D.C. (PRWEB)
November 16, 2017
At a Nov. 14 hearing on gene editing technology, the Senate Committee on Health, Education, Labor, and Pensions listened to testimony from experts in the field about scientific, regulatory, and ethical aspects of the topic. Two of the three invited witnesses at the hearing are members of the American Society of Gene and Cell Therapy (ASGCT)—Matt Porteus, MD, PhD, a member of the ASGCT Board of Directors, and Katrine Bosley.
The speakers provided the committee with information on gene editing, a more precise form of gene therapy in which a nuclease (an enzyme) is used to break the DNA at the site of an abnormality (mutation) in a gene, to treat disease—a method likened to correcting typographical errors in the DNA. Gene editing technologies are now reaching the human clinical trial stage of research with a report of the first in vivo gene editing in the United States released just the day after the congressional hearing. Dr. Porteus indicated in his testimony that he expects multiple clinical trials to occur within the next 12-18 months.
Dr. Porteus, a pediatric hematologist/oncologist in the bone marrow transplant unit and an associate professor at the Stanford University School of Medicine, informed the committee of the great potential for gene editing to provide durable and potentially curative treatment for the tens of millions of people in the United States who have a variety of devastating genetic diseases, most of which affect children and have no current treatment, including sickle cell…